Palvella Therapeutics Inc (PIRS)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA Summary
PIRS Chart
Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference
Poster presentations include data supporting QTORINâ„¢ rapamycin 3.9% anhydrous gel as a potential targeted therapy for the treatment of microcystic lymphatic malformations and a review of the Phase 3 SELVA study Poster presentations include data supporting QTORINâ„¢ rapamycin 3.9% anhydrous gel as a potential targeted therapy for the treatment of microcystic lymphatic malformations and a review of the Phase 3 SELVA study
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations
FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) and Palvella Therapeutics, Inc. is fair to Pieris shareholders. Pre-merger Pieris shareholders are expected to own approximately 18% of the combined company. Halper Sadeh encourages Pieris shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halper.
Palvella Therapeutics Inc Dividends
Palvella Therapeutics Inc Earnings
| 13 May 2025 Date | | - Cons. EPS | - EPS |
| 27 Mar 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 14 Aug 2024 Date | | - Cons. EPS | - EPS |
| 12 Aug 2024 Date | | - Cons. EPS | - EPS |
| 13 May 2025 Date | | - Cons. EPS | - EPS |
| 27 Mar 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 14 Aug 2024 Date | | - Cons. EPS | - EPS |
| 12 Aug 2024 Date | | - Cons. EPS | - EPS |
Palvella Therapeutics Inc (PIRS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Palvella Therapeutics Inc ever had a stock split?
Palvella Therapeutics Inc Profile
| Biotechnology Industry | Healthcare Sector | Mr. Stephen S. Yoder J.D. CEO | NASDAQ (CM) Exchange | 720795103 Cusip |
| US Country | 46 Employees | - Last Dividend | 23 Apr 2024 Last Split | 13 Apr 2015 IPO Date |
Overview
Pieris Pharmaceuticals, Inc. is an innovative biotechnology firm established in 2001 with a head office located in Boston, Massachusetts. The company is engaged in the discovery and development of advanced biotechnological applications with a particular emphasis on immuno-oncology (IO). Through its strategic partnerships and cutting-edge research, Pieris Pharmaceuticals aims to catalyze advancements in the treatment of cancer and other serious diseases by harnessing the power of its proprietary 4-1BB bispecifics programs.
Products and Services
- S095012 (PRS-344)
A groundbreaking bispecific Mabcalin compound co-developed with Les Laboratoires Servier and Institut de Recherches Internationales Servier, S095012 (PRS-344) uniquely targets PD-L1 and 4-1BB. This dual-targeting mechanism is designed to enhance the immune system's ability to fight cancer. Currently under phase 1 clinical studies, the compound promises to be a significant advancement in IO therapies.
- SGN-BB228 (PRS-346)
In collaboration with Pfizer Inc., SGN-BB228 (PRS-346) is a novel CD228 x 4-1BB bispecific antibody-Anticalin compound. By targeting CD228 and 4-1BB, it leverages a unique pathway to stimulate an immune response against cancer cells. This product is part of Pieris Pharmaceuticals' effort to develop more effective cancer treatments and is also in phase 1 of clinical research.
- BOS-342 (PRS-342)
A collaboration with Boston Pharmaceuticals has given rise to BOS-342 (PRS-342), a bispecific Mabcalin compound targeting GPC3 and 4-1BB. This innovative approach aims at exploiting the tumor antigen GPC3 for the therapeutic engagement of 4-1BB, a costimulatory receptor on T cells. The product is designed to bolster the immune system's ability to target and destroy cancer cells and is in the early stages of clinical testing.
Contact Information
